Carcinoembryonic antigen

Carcinoembryonic antigen (CEA) is a glycoprotein involved in cell adhesion. It is normally produced during fetal development, but the production of CEA stops before birth. Therefore, it is not usually present in the blood of healthy adults, although levels are raised in heavy smokers. CEA was first identified in 1965 by Phil Gold and Samuel O. Freedman in human colon cancer tissue extracts.^[1] It was found that serum from individuals with colorectal, gastric, pancreatic, lung and breast carcinomas had higher levels of CEA than healthy individuals.

Additional recommended knowledge

12 Practical Tips for Correct Weight Handling

Daily Visual Balance Check

Don't let static charges disrupt your weighing accuracy

CEA measurement is mainly used as a tumor marker to identify recurrences after surgical resection. Elevated CEA levels should return to normal after surgical resection, as elevation of CEA during follow up is an indicator of recurrence of tumour. CEA levels may also be raised in some non-neoplastic conditions like ulcerative colitis, pancreatitis and cirrhosis.

CEA and related genes make up the CEA family belonging to the immunoglobulin superfamily. In humans, the carcinoembryonic antigen family consists of 29 genes, 18 of which are normally expressed.^[2]

References

1. ^ Gold P, Freedman SO. Demonstration of tumor-specific antigens in human colonic carcinomata by immunological tolerance and absorption techniques. J Exp Med 1965;121:439. PMID 14270243.
2. ^ Hammarstrom S. The carcinoembryonic antigen (CEA) family: structures, suggested functions and expression in normal and malignant tissues. Semin Cancer Biol 1999;9:67-81. PMID 10202129.